ArticlePCN reports : psychiatry and clinical neurosciences2025
Case series: Potential use of guanfacine for safer management of behavioral disturbances in patients with dementia.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A new hope: locus coeruleus-norepinephrine system at the nexus of neuropsychiatric symptoms.Molecular psychiatry · 2026Review
- Case series: Potential use of guanfacine for safer management of behavioral disturbances in patients with dementia.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Behavioral and psychological symptoms of dementia (BPSD), including irritability, agitation, and anxiety, are common and cause significant distress for both patients and caregivers. These symptoms are linked to caregiver distress and early institutionalization, with disruptive behaviors like aggression often leading to emergency care. While antipsychotics have been used to manage BPSD, they are associated with serious side-effects. There is a critical need for alternative effective and safer treatments that can reduce reliance on antipsychotics. In 2022, the therapeutic use of guanfacine to manage these symptoms in elderly dementia patients was suggested in two cases. Case Presentation: We present two additional clinical cases in which guanfacine was potentially effective in addressing behavioral disturbances in dementia patients at low doses and over a short period of time. Conclusion: Guanfacine may serve as a beneficial and well-tolerated option for managing behavioral issues in dementia patients, potentially reducing the reliance on antipsychotics and minimizing the risk of related side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.